

BD

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
5 December 2002 (05.12.2002)

PCT



(10) International Publication Number
WO 02/096865 A1

- (51) International Patent Classification⁷: **C07C 309/66, A61K 31/19**
- (74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).
- (21) International Application Number: **PCT/SE02/01040**
- (22) International Filing Date: **30 May 2002 (30.05.2002)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
0101979-3 1 June 2001 (01.06.2001) SE
0201004-9 2 April 2002 (02.04.2002) SE
- (71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **EHRL, Robert** [DE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **IOANNIDIS, Panagiotis** [GR/SE]; Ovanbygränd 16, S-163 70 Spånga (SE). **MACKINTOSH, William** [ZA/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE).
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.**
- (84) Designated States (regional): **ARIPO** patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), **Eurasian** patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), **European** patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), **OAPI** patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,**

[Continued on next page]

(54) Title: **PROCESS FOR THE PREPARATION 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE**

WO 02/096865 A1

(57) Abstract: A process for the preparation of a compound of formula (I) in which R represents H or an acid protecting group which comprises reacting a compound of formula (II) in which R is as previously defined with a compound of formula (III) wherein X is a suitable leaving group in the presence of a base and a phase transfer catalyst at a temperature in the range 50°C to 150°C.



CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)


Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Process for the preparation 3-aryl-2-hydroxypropionic acid derivative

The present invention relates to an improved process for the preparation of the compound 2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid, as shown in formula I below



or the (R) or the (S) enantiomer thereof, or a pharmaceutically-acceptable salt thereof, and solvates thereof.

The above compound is intended for therapeutic use in the Insulin Resistance Syndrome (IRS) including type 2 diabetes mellitus, which refers to a cluster of manifestations including insulin resistance with accompanying hyperinsulinaemia, possible type 2 diabetes mellitus, arterial hypertension, central (visceral) obesity, dyslipidaemia observed as deranged lipoprotein levels typically characterised by elevated VLDL (very low density lipoproteins), small dense LDL particles and reduced HDL (high density lipoprotein) concentrations and reduced fibrinolysis.

Recent epidemiological research has documented that individuals with insulin resistance run a greatly increased risk of cardiovascular morbidity and mortality, notably suffering from myocardial infarction and stroke. In type 2 diabetes mellitus atherosclerosis related conditions cause up to 80% of all deaths.


In clinical medicine there is awareness of the need to increase the insulin sensitivity in IRS suffering patients and thus to correct the dyslipidaemia which is considered to cause the

accelerated progress of atherosclerosis. However, currently this is not a universally well defined disease.


The compound of formula I is disclosed in PCT Publication Number WO99/62872. Two
5 alternative processes are disclosed for the preparation of the compound of formula I in Examples 1 and 2 of the application. We have discovered an improvement in relation to one of the processes disclosed.

Specifically we have found an improved method for the synthesis of the penultimate
10 esterified intermediate, the final step of the reaction being the conversion of the ester group into the acid of the final product.


Accordingly the present invention provides a process for the preparation of a compound of formula I



in which R represents H or an acid protecting group which comprises reacting a compound of formula II




in which R is as previously defined with a compound of formula III




wherein X is a suitable leaving group in the presence of a base and a phase transfer catalyst at a temperature in the range 50°C to 150°C.


In another aspect the present invention provides a process for the preparation of a compound of formula I



in which R represents H or an acid protecting group which comprises reacting a compound of formula II




in which R is as previously defined with a compound of formula III




wherein X is a suitable leaving group in the presence of an aqueous solution of a base and a phase transfer catalyst at a temperature in the range 50°C to 150°C.


- 5 In another aspect the present invention provides a process for the preparation of a compound of formula I



- 10 in which R represents H or an acid protecting group which comprises reacting a compound of formula II



in which R is as previously defined with a compound of formula III



wherein X is a suitable leaving group in the presence of a base in solid form and a phase transfer catalyst at a temperature in the range 50°C to 150°C.

The process may be carried out in a melt or in the presence of a suitable solvent for the compounds of formulae II and III. Preferably the process is carried out at a temperature in the range of 80°C to 130°C and most preferably in the range of 90°C to 110°C.

5 The term "acid protecting group" means that the acid is protected from reaction by forming a suitable acid derivative such as an ester or amide or by other means of protection of carboxylic acid groups known in the art. Examples of suitable means of protection and acid derivatives (as well as means of formation and eventual deprotection), may be found in T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis", Third
10 Edition, John Wiley & Sons, New York, 1999. The nature of the ester is not important in the performance of the process since its function is to act as a protecting group. The improvements relate to the application of phase transfer catalysis to the process. Preferably R is H, benzyl or a (1-4C)alkyl group, such as methyl, ethyl or propyl. More preferably R is a (1-4C)alkyl group. Most preferably R is ethyl.

15

Each of the aforementioned processes may also comprise an additional step in which the the protecting group is removed to produce a compound of formula I in which R is H. Preferably R is an ester and the protecting group removal step comprises a hydrolysis step. The hydrolysis step may be acid or base catalysed (for example using lithium hydroxide).
20 Optionally an organic liquid may be present in the hydrolysis step for example acetone, 2-butanone, methanol, ethanol, tetrahydrofuran or dioxane. Converting the acid ester derivative may be accomplished simply by hydrolysis (acidic or alkaline or enzymatic) of the ester to the acid, such a step being known to the skilled person, such as described in the examples below and in Example 2 i) of WO99/62872.

25

Suitably X is halo, for example bromo, chloro or iodo, an optionally substituted phenylsulfonyloxy group, in particular (4-methylphenyl)sulfonyloxy group or 2,4,6-triisopropylphenylsulfonyloxy group or an alkylsulphonyloxy group for example methanesulphonyloxy. Preferably X is a methanesulphonyloxy group.

30

Suitable bases include carbonates, hydrogen carbonates or hydroxides particularly of alkali metals. Preferably the base is sodium carbonate, sodium hydrogen carbonate, potassium carbonate or potassium hydrogen carbonate.

- 5 Suitably the phase transfer catalyst is a crown ether, a polyethylene glycol or a quaternary ammonium salt particularly with a halide counterion. Suitable crown ethers include 18 crown 6, dicyclohexyl[18-crown-6] and dibenzo[18-crown-6]. Suitable polyethylene glycols include PEG 400. Suitable quaternary ammonium salts include tetrahexylammonium bromide, methyltrioctylammonium chloride and tetraoctylammonium bromide.

10

Suitably the molar ratio of the compound of formula III to the compound of formula II is in the range of 0.5 to 10, preferably in the range 0.8 to 4 and more preferably in the range of 1.0 to 3 and most preferably is in the range of 1.2 to 1.6.

- 15 Suitably the weight ratio of the phase transfer catalyst to the compound of formula II is in the range of 0.05 to 10, preferably in the range 0.1 to 5 and more preferably in the range of 0.15 to 3.

- 20 Suitably the molar ratio of the base to the compound of formula II is in the range of 0.5 to 10, preferably in the range 0.8 to 4 and more preferably in the range of 1.0 to 3 and most preferably is in the range of 1.2 to 1.6.

- 25 The solvent, if used, is an organic solvent. The organic solvent may be either a protic or an aprotic solvent, preferably an aprotic solvent such as 2-butanone, *iso*-butyl methyl ketone, acetone, dimethylsulfoxide, *N,N*-dimethylformamide or *N*-methylpyrrolidone. Since the process is to be performed at a temperature in the range of 50 °C to 150 °C it will be appreciated by those skilled in the art that the process may optionally be performed under pressure in order to achieve the desired reaction temperature with solvents which have a boiling point below the desired reaction temperature.


30

The process of the invention has the following advantages. The reaction times are more rapid than the reactions known in the prior art and therefore the process is less costly to run. In


addition the process gives higher yields and the product is of a higher purity than previously disclosed processes for the preparation of the compound of formula I. Further, the process is consistently reproducible and robust.

- 5 In the process where a melt is used greater purity is achieved and the reaction is more volume effective, i.e the same reaction vessel will produce greater yields.


In another aspect the present invention provides a process for the preparation of a compound of formula I



in which R represents H which comprises reacting a compound of formula II



in which R represents an acid protecting group with a compound of formula III



wherein X is a suitable leaving group in the presence of a base in solid form and a phase transfer catalyst at a temperature in the range 50°C to 150°C to give a compound of formula I in which R

is an acid protecting group and then removing the protecting group to give a compound of formula I in which R is H.

- 5 In a preferred aspect the process provides the S-enantiomer of the compound of formula I in which R is H by using the S-enantiomer of the compound of formula II in which R represents H or an acid protecting group followed by hydrolysis when R is an acid protecting group.

The compound of formula I in which R is H may be purified by recrystallisation. Suitable
10 recrystallisation solvents include one or more of the following ethanol, water, isopropylacetate, isopropanol, isooctane and toluene.

The invention is illustrated by the following non-limiting examples.

15

Abbreviations

EtOAc = ethyl acetate

HPLC = high-pressure liquid chromatography

20 i-PrOAc = isopropyl acetate

PEG = polyethylene glycol

MEK = Methyl ethyl ketone or butan-2-one

MIBK = Methyl isobutyl ketone or 3 methylbutan-2-one

EtOH = ethanol

25

Preparation of Starting Material

2-(4-Methanesulfonyloxyphenyl)ethylmethanesulfonate was prepared as described in
WO99/62872.

30

Example 1**Ethyl (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl] propanoate**

2-(4-Methanesulfonyloxyphenyl)ethylmethanesulfonate (298.5 g, 1.01 mol), ethyl (2S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate (96.7 g, 406 mmol) and PEG-400 (32.5 g, 81 mmol) were melted together at 110 °C. Na₂CO₃ (56.8 g, 536 mmol) was then added under vigorous stirring. The reaction was continued at this temperature for 5.5 hours. (HPLC control of conversion >95%). The mixture was then cooled to 45 °C. Acetone (500 ml) was added. The mixture was stirred until all organic material was dissolved. The inorganic salts were then filtered off. The salts were washed twice with acetone (2 x 300 ml). The acetone solution of the title compound was used directly in the next step.

(S)-2-Ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl] propanoic acid

To the acetone solution containing ethyl (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoate was charged water (200 ml). Under vigorous stirring concentrated NaOH (aq) (34 ml, 568 mmol) was charged. The solution was then heated to +30 °C and the reaction continued for 6 hours (HPLC control conversion >99%) under vigorous stirring. The reaction was quenched with EtOAc (140 ml). When the pH was 11, evaporation of organic solvents was started at about 50 °C under vacuum. When all volatile solvents were removed (750 ml solution remaining in the reactor), water (100 ml) was charged and the distillation continued until 520 ml of the solution remained in the reactor. The solution was cooled to 20 °C and water (280 ml) was charged. The solution was then extracted 3 times with EtOAc (2 x 600 ml, 1 x 400 ml).

25

The pH was then corrected to 2-2.5 using 25 % H₂SO₄. The solution was heated to 50 °C and remaining EtOAc was distilled off under vacuum. The evaporation was terminated when water started to distil. The acidic water solution was then extracted with toluene (605 ml) at 50 °C. The toluene phase was washed with water (380 ml) at 50 °C. The toluene solution was then cooled to 20 °C over about 1 hour. At 20 °C the solution was seeded with (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid. The

30

slurry formed was then cooled to 8 °C and left crystallising over night. The product was filtered and washed with 8 °C toluene (160 ml).

Example 2

5 2-(4-Methanesulfonyloxyphenyl)ethylmethanesulfonate

2-(4-Hydroxyphenyl)ethanol (20.0 g, 143.7 mmol) was dissolved in 2-butanone (MEK, 200 ml) and triethylamine (44.3 ml, 316.2 mmol). The mixture was cooled to 3 °C after a clear solution was obtained. Methanesulfonyl chloride (23.4 ml, 301.8 mmol) was then added during about 15 minutes keeping the temperature below 17 °C. The conversion was checked
10 25 minutes after all the methanesulfonyl chloride was added. The slurry was cooled to 6 °C and the salts formed were filtered off and washed with +8 °C 2-butanone (MEK, 50 ml). The MEK-solution of 2-(4-methanesulfonyloxyphenyl)-ethylmethanesulfonate was then used in the following step.

15 Ethyl (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl] propanoate

Ethyl (S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate (10.0 g, 41.5 mmol) was dissolved in the MEK solution containing 2-(4-methanesulfonyloxyphenyl)ethylmethanesulfonate (ca 105 ml, 60.2 mmol). When a homogenous solution was formed, PEG-400 (4.0 g, 40 weight% to ethyl
20 (S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate) and K₂CO₃ (8.67 g, 62.2 mmol) were added under vigorous stirring. The mixture was allowed to react at reflux, 79 °C for about 6 hours under vigorous stirring. The reaction mixture was cooled to 26 °C and MEK (10 ml) was added. Water (50 ml) was added and the phases were separated. The organic layer was washed once more with water (20 ml). The organic phase was then used in the following step.

25

(S)-2-Ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl] propanoic acid

To the 2-butanone solution (total volume about 50 ml) of ethyl (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoate (7.55 g, 17.2 mmol) was added
30 acetone (25 ml), water (5 ml) and NaOH (3M, 7.5 ml). Acetone (10 ml) was added and the mixture was heated to 30 °C. After about 3.5 hours the mixture was cooled to 25 °C and EtOAc (20 ml) was added. The mixture was then evaporated under vacuum, removing the

volatile solvents. During the evaporation a further portion of water (40 ml) was added. EtOAc (40 ml) was added and the mixture extracted. The phases were separated and the water layer was washed once more with EtOAc (15 ml). Toluene (30 ml) was then added and the pH of the mixture was adjusted to 2.1 with H₂SO₄ (conc). The layers were separated and the water layer extracted once more with toluene (8 ml). The combined organic layers were washed once with water (8 ml). The toluene solution was then evaporated down to a volume of 20 ml. The solution was seeded and crystallised while cooling. Toluene (6 ml) was added to make the slurry more mobile. The product was filtered and washed once with cold toluene (10 ml). The crystals were then dried under vacuum.

Example 3

2-(4-Methanesulfonyloxyphenyl)ethylmethanesulfonate (1.64 g, 5.41 mmol) was dissolved in 2-butanone (10.0 ml) at 22 °C. Ethyl (2S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate (1.0 g, 4.16 mmol), 18-Crown-6 (0.06 g, 0.21 mmol) and K₂CO₃ (0.81 g, 5.82 mmol) were added. The mixture was boiled under reflux for 4 hours. A conversion of 93% was reached.

Example 4

2-(4-Methanesulfonyloxyphenyl)ethylmethanesulfonate (3.09g, 10.5 mmol), ethyl (S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate (1.00 g, 4.20 mmol) and dibenzo-18-Crown-6 (0.15 g, 0.42 mmol) were mixed together. The mixture was heated to 90 °C and K₂CO₃ (1.25 g, 5.46 mmol) was added. The reaction was allowed to proceed at 110 °C for 4 hours. A conversion of 91 % was reached.

Example 5

A mixture of 2-(4-methanesulfonyloxyphenyl)ethylmethanesulfonate (296.5 g / 1.6 mol eq), ethyl (S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate (150 g / 1.00 mol eq), PEG-400 (50.36 g / 0.2 mol eq / 0.30 rel vol), Na₂CO₃ (88.74 g / 1.33 mol eq) and water (300.0 g / 26.5 mol eq / 2.0 rel vol) was boiled under reflux with vigorous stirring for about 3-7 h. The mixture was cooled to T_i = 85-95 °C and the phases are separated. Acetone (316.0 g /

8.64 mol eq / 2.7 rel vol, $T_b = 56.2\text{ }^{\circ}\text{C}$) was charged to the organic phase at $T_i < 55\text{ }^{\circ}\text{C}$.

Cooling was continued down to $T_i = 25\text{ }^{\circ}\text{C}$.

The acetone solution containing ethyl (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxy-

phenyl)ethoxy)phenyl] propanoate was kept at $T_i = 25\text{ }^{\circ}\text{C}$ in the reactor. $\text{LiOH}\cdot\text{H}_2\text{O}$ powder

(34.3 g / 1.3 mol eq) dissolved in water (600.0 g / 4.0 rel vol) was charged continuously over

30 minutes under vigorous stirring at $25\pm 5\text{ }^{\circ}\text{C}$. The reaction was continued for 1-3 hours. The

reaction was quenched by addition of EtOAc (40.5 g / 0.73 mol eq / 0.3 rel vol) at $T_i = 25\pm 5$

$^{\circ}\text{C}$. Acetone, EtOH and EtOAc was removed from the solution by vacuum evaporation at

$T_i \leq 35\text{ }^{\circ}\text{C}$. The solution was washed once with isopropyl acetate (5.0 rel vol / 750.0 ml) $T_i =$

35 $^{\circ}\text{C}$. The water layer was evaporated down to a volume of 600 ml / 4.0 rel vol prior to

crystallisation and also to remove residues of EtOAc.

Acetic acid (629.4 g / 600 ml / 4.0 rel vol) was charged to the solution under good stirring at

25 $^{\circ}\text{C}$ and a clear solution should be formed. The solution was seeded using (S)-2-ethoxy-3-

[4-(2-{4-methanesulfonyloxyphenyl)ethoxy)phenyl] propanoic acid (0.75 g). The solution

was cooled to 20 $^{\circ}\text{C}$. A mixture of water (600 g / 600 ml / 4 rel vol) and sulphuric acid (27.6 g

/ 15.0 ml / 0.1 rel vol) was charged to the slurry keeping the temperature at 20 $^{\circ}\text{C}$. After the


water charge, pH was checked and adjusted to 2-2.5 using H_2SO_4 or $\text{LiOH}\cdot\text{H}_2\text{O}$. The slurry

was cooled to -4 $^{\circ}\text{C}$. The slurry was left at -4 $^{\circ}\text{C}$ for 19 hours. The slurry was filtered and


washed with water (2 x 450 ml / 2 x 3.0 rel vol). (S)-2-Ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl)ethoxy)phenyl] propanoic acid was dried under vacuum at 40 $^{\circ}\text{C}$.

Claims


1. A process for the preparation of a compound of formula I



in which R represents H or an acid protecting group which comprises reacting a compound of formula II




in which R is as previously defined with a compound of formula III



wherein X is a suitable leaving group in the presence of a base and a phase transfer catalyst at a temperature in the range 50°C to 150°C.


2. A process according to claim 1 for the preparation of a compound of formula I

14




in which R represents H or an acid protecting group which comprises reacting a compound of formula II

5




in which R is as previously defined with a compound of formula III



10


wherein X is a suitable leaving group in the presence of an aqueous solution of a base and a phase transfer catalyst at a temperature in the range 50°C to 150°C.

3. A process according to claim 1 for the preparation of a compound of formula I




15

in which R represents H or an acid protecting group which comprises reacting a compound of formula II



in which R is as previously defined with a compound of formula III



wherein X is a suitable leaving group in the presence of a base in solid form and a phase transfer catalyst at a temperature in the range 50 °C to 150 °C.

4. A process according to any one of the preceding claims which comprises an additional step in which the protecting group is removed to produce a compound of formula I in which R is H.


5. A process according to claim 4 in which the acid protecting group is removed by hydrolysis.

6. A process according to any one of claims 3 to 5 in which the process is carried out as a melt.


7. A process according to any preceding claim in which R is a (1-4C)alkyl group.

8. A process according to any preceding claim in which X is halo, an optionally substituted phenylsulfonyloxy group or an alkylsulphonyloxy group.


9. A process according to any preceding claim in which the base is selected from carbonates, hydrogen carbonates or hydroxides of alkali metals.
10. A process according to any preceding claim in which the phase transfer catalyst is a crown ether, a polyethylene glycol or a quaternary ammonium salt particularly with a halide counterion.
11. A process according to either one of claims 1 or 2 in which the process is carried out in the presence of a suitable solvent for the compounds of formulae II and III.
12. A process according to claim 11 in which the solvent is selected from 2-butanone, *iso*-butyl methyl ketone, acetone, dimethylsulfoxide, *N,N*-dimethylformamide, or *N*-methylpyrrolidone.
13. A process according to any preceding claim in which the compound of formula I is the S enantiomer.
14. A process according to claim 3 for the preparation of a compound of formula I



- in which R represents H which comprises reacting a compound of formula II



- in which R represents an acid protecting group with a compound of formula III



wherein X is a suitable leaving group in the presence of a base in solid form and a phase transfer catalyst at a temperature in the range 50 °C to 150 °C to give a compound of formula I
5 in which R is an acid protecting group and then removing the protecting group to give a compound of formula I in which R is H.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/01040

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07C 309/66, A61K 31/19

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07C, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9962872 A1 (ASTRA AKTIEBOLAG), 9 December 1999 (09.12.99), claim 2 --	1-14
A	WO 0140170 A1 (ASTRAZENECA AB), 7 June 2001 (07.06.01), claims 1-8 -- -----	1-14

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

27 August 2002

Date of mailing of the international search report

09-09-2002

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

FERNANDO FARIETA/BS
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

Information on patent family members

06/07/02

International application No.

PCT/SE 02/01040

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	9962872	A1	09/12/99	AU	1182399 A	31/05/99
				AU	4667199 A	20/12/99
				AU	4667299 A	20/12/99
				BR	9910921 A	06/03/01
				BR	9910928 A	13/02/01
				CN	1311772 T	05/09/01
				CN	1312795 T	12/09/01
				EE	200000720 A	15/04/02
				EE	200000725 A	17/06/02
				EP	1084102 A	21/03/01
				EP	1084103 A	21/03/01
				HR	20000782 A	30/06/01
				JP	2002516899 T	11/06/02
				JP	2002516900 T	11/06/02
				NO	20006115 A	07/02/01
				NO	20006116 A	02/02/01
				PL	344681 A	19/11/01
				PL	345205 A	03/12/01
				SE	9801992 D	00/00/00
				SK	17682000 A	06/08/01
				SK	17692000 A	10/05/01
				TR	200003581 T	00/00/00
				TR	200003583 T	00/00/00
				TW	446696 B	00/00/00
				US	6258850 B	10/07/01
				US	2001034371 A	25/10/01
				WO	9962871 A	09/12/99
WO	0140170	A1	07/06/01	AU	2240101 A	12/06/01
				NO	20022603 D	00/00/00
				SE	9904422 D	00/00/00
				SE	9904418 D	00/00/00

THIS PAGE BLANK (USPTO)